Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: A randomized study

Reproductive BioMedicine Online

Volumn 13, Issue 2, 2006, Pages 235-245

  Huirne, Judith A F ^a   van Loenen, Andre C D ^a   Donnez, Jacques ^b   Pirard, Céline ^b   Homburg, Roy ^a   Schats, Roel ^a   McDonell, Joseph ^a   Lambalk, Cornelis B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

GnRH antagonist; IVF; Oral contraceptive; Pretreatment; Programming

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; GONADORELIN ANTAGONIST; ITURELIX; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM; FATIGUE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE DETERMINATION; HUMAN; INJECTION SITE REACTION; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; METRITIS; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; OOCYTE; OVARY CYST; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 33747067960     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60621-9     Document Type: Article

References (34)

1. Albano C, Felberbaum RE, Smitz J et al. 2000 The European Cetrorelix Study Group 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Human Reproduction 15, 526-531.
2. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
3. Al-Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
4. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI 2005 GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reproductive BioMedicine Online 10, 567-570.
5. Bajusz S, Kovacs M, Gazdag M et al. 1988 Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proceedings of the National Academy of Sciences of the USA 85, 1637-1641.
6. Barmat LI, Chantilis SJ, Hurst BS, Dickey RP 2005 A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women with oral contraceptives before in vitro fertilization. Fertility and Sterility 83, 321-330.
7. Borm G, Mannaerts B, The European Orgalutran Study Group 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 15, 1490-1498.
8. Bosch E, Vancia I, Escudero E et al. 2003 Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertility and Sterility 80, 1444-1449.
9. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ ICSI cycles: a prospective randomized study. Human Reproduction 19, 1979-1984.
10. De Ziegler D, Jaaskelainen AS, Brioschi PA et al. 1998 Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Human Reproduction 13, 561-564.
11. Del Prato L, Bornini A Use of antagonists in ovarian stimulation protocols. Reproductive BioMedicine Online 10, 330-338.
12. European and Middle East Orgulatran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
13. Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
14. Franchin R, Salomon L, Caselo-Branco A et al. 2003 Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Human Reproduction 18, 2698-2703.
15. Frydman R, Forman R, Rainhorn JD et al. 1986 A new approach to follicular stimulation for in vitro fertilization-programmed oocyte retrieval. Fertility and Sterility 46, 657-662.
16. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
17. Huirne JA, Lambalk CB 2001 Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358, 1793-1803.
18. Huirne JA, Hugues JN, Pirard C et al. 2006 Cetrorelix in an OC pretreated stimulation cycle compared to buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction 21, 1408-1415.
19. Huirne JA, Van Loenen AC, Schats R et al. 2005 Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Human Reproduction 20, 359-367.
20. Huirne JA, van Loenen AC, Schats R et al. 2004 Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: Antide and hormone levels. Human Reproduction 19, 2206-2215.
21. Hwang JL, Seow KM, Lin YH et al. 2004 Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction 19, 1993-2000.
22. Kol S 2005 To add or not to add LH: consideration of LH concentration changes in individual patients. Reproductive BioMedicine Online 11, 664-666.
23. Kolibianakis EM, Papanikolaou EG, Camus M et al. 2006 Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Human Reproduction 21, 352-357.
24. Kolibianakis EM, Tarlatzis B, Devroey P 2005 GnRH antagonists in IVF. Reproductive BioMedicine Online 10, 705-712.
25. Kolibianakis EM, Albano C, Kahn J et al. 2003a Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility 79, 873-880.
26. Kolibianakis EM, Albano C, Camus M et al. 2003b Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: Effect on hormonal levels and follicular development in in vitro fertilization cycles. Journal of Clinical Endocrinology and Metabolism 88, 5632-5637.
27. Merviel P, Antoine JM, Mathieu E et al. 2004 Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertility and Sterility 82, 119-125.
28. Obruca A, Fischl F, Huber JC 2000 Scheduling OPU in GnRH antagonist cycles. IVF Journal für Fertilität und Reproduction, Austria.
29. Olivennes F, Alvarez S, Bouchard P et al. 1998 The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Human Reproduction 13, 2411-2414.
30. Rijnders PM, Lens JW 1993 The embryo. In: Bras M, Lens JW, Rijnders PM et al. (eds), IVF Laboratory: Aspects of In Vitro Fertilization. Organon BV Nederland, Etten Leur.
31. Rivier J, Porter J, Hoeger C et al. 1992 Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. Journal of Medicinal Chemistry 35, 4270-4278.
32. Rombauts L, Healy D, Norman RJ 2006 Comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Human Reproduction 21,95-103.
33. Templeton A, van Look P, Lumsden MA et al. 1984 The recovery of preovulatory oocytes using a fixed schedule of ovulation induction and follicle aspiration. British Journal of Obstetrics and Gynaecology 91, 148-154.
34. Van Heusden AM, Fauser BC 1999 Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 59, 237-243.